CDER Interim Response Letter to Age Reversal Unity

FDA CDER provided interim correspondence in response to Age Reversal Unity's pending submission (FDA-2025-P-4985). The letter does not approve, deny, or establish new regulatory requirements but instead communicates preliminary feedback typical of Pre-Request for Designation proceedings. This type of interim response often requests additional data, clarification of product characterization, or identification of regulatory pathway options.

Affected parties, primarily pharmaceutical or biotech companies seeking FDA feedback on investigational products, should treat such interim letters as actionable guidance requiring prompt response. While not binding, the agency's feedback shapes subsequent submission strategy and determines the timeline for obtaining a formal response. Companies should ensure adequate documentation of all communications with FDA and prepare targeted responses to any agency requests.